Brokerages forecast that NovaBay Pharmaceuticals, Inc. (NYSE:NBY) will post ($0.12) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for NovaBay Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.10). NovaBay Pharmaceuticals reported earnings of ($0.36) per share in the same quarter last year, which would indicate a positive year over year growth rate of 66.7%. The company is expected to issue its next earnings results on Thursday, August 10th.
According to Zacks, analysts expect that NovaBay Pharmaceuticals will report full-year earnings of ($0.54) per share for the current year, with EPS estimates ranging from ($0.60) to ($0.47). For the next financial year, analysts expect that the firm will post earnings of ($0.07) per share, with EPS estimates ranging from ($0.13) to ($0.02). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for NovaBay Pharmaceuticals.
NBY has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of NovaBay Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 11th. Laidlaw initiated coverage on shares of NovaBay Pharmaceuticals in a research note on Monday, March 27th. They issued a “buy” rating and a $10.00 price objective on the stock. Maxim Group reaffirmed a “hold” rating on shares of NovaBay Pharmaceuticals in a research note on Friday, March 24th. Roth Capital initiated coverage on shares of NovaBay Pharmaceuticals in a research note on Monday, June 5th. They issued a “buy” rating and a $5.50 price objective on the stock. Finally, HC Wainwright set a $6.00 price objective on shares of NovaBay Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, March 26th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $6.88.
COPYRIGHT VIOLATION NOTICE: This story was first published by WKRB News and is owned by of WKRB News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.wkrb13.com/markets/2230683/0-12-eps-expected-for-novabay-pharmaceuticals-inc-nby-this-quarter.html.
NovaBay Pharmaceuticals (NYSE:NBY) remained flat at $2.50 during midday trading on Wednesday. The company’s stock had a trading volume of 15,904 shares. The firm has a 50-day moving average price of $2.84 and a 200 day moving average price of $3.55. NovaBay Pharmaceuticals has a 12 month low of $2.12 and a 12 month high of $5.29. The firm’s market cap is $38.27 million.
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230683/0-12-eps-expected-for-novabay-pharmaceuticals-inc-nby-this-quarter.html
Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.